Myles Greenberg, MD, MBA

CEO, Alucent Biomedical
Dr. Myles Greenberg comes to Alucent Biomedical with more than 20 years of experience in growing healthcare, medical technology and life sciences firms as an entrepreneur, operating executive, board member, clinician and investor. Prior to joining Alucent, he served as chief development officer at IntegraMed America, a private equity backed healthcare services firm. Previously, Dr. Greenberg spent most of his career as an early-stage venture capital investor with CHL Medical Partners, HealthInvest Equity Partners and Pappas Ventures. As a start-up venture investor and board member, he often served as lead director or in an interim management role at many dynamic companies in the biotechnology, medical device, and healthcare services sectors, such as Angiomics (acquired by PDL BioPharma), Flowcardia (acquired by CR Bard), Liposcience (acquired by LabCorp), Millennium Pharmacy Systems (acquired by PharMerica), Oriel Therapeutics (acquired by Novartis / Sandoz), NuVasive (Nasdaq: NUVA), Syntonix Pharmaceuticals (acquired by Biogen Idec), and Vascular Pathways (acquired by CR Bard). In addition to leading the Alucent team, Dr. Greenberg currently serves on the board of directors of Urgent Care Centers of New England (d/b/a CareWell Urgent Care), a company he co-founded, and as Entrepreneur-In-Residence at the University of Utah Center for Medical Innovation. Dr. Greenberg began his career as a faculty physician and hospital administrator at Beth Israel Deaconess Medical Center / Harvard Medical School in Boston. He holds a Master of Business Administration from Harvard Business School, Doctor of Medicine from Yale University School of Medicine and a Bachelor of Applied Science from the University of Pennsylvania School of Engineering and Applied Science and is a Diplomate of the American Board of Emergency Medicine.

Jared Bauer, MBA

CEO, Seek Labs
Jared Bauer is CEO of Seek Labs, a diagnostics and pharmaceutical development company, he co-founded in 2016. Bauer has focused his professional endeavors on the medtech industry and is passionate about healthcare innovation. In 2012, he acquired BurnFree Products, and led the team to expand BurnFree distribution to 58 countries before a successful exit in 2016. He also currently serves as trustee of The Oliver Fund (a non-profit he co-founded with his wife, Sarah), Chairman of BioHive, and previously served as an adjunct professor of entrepreneurship at Ensign College. He holds a BS in Economics from the University of Utah, and an MBA from Boise State University.

David Bearss, PhD

CEO, Halia Therapeutics
Dr. David J. Bearss is an experienced entrepreneur and drug developer with 20 plus years’ experience in the academic and industry settings. He is an expert in small molecule drug development and in the use of genetic model systems in drug discovery and has deep experience in translational research focused on drug development and the use of genetic markers to predict drug sensitivity. Dave has discovered 16 compounds that have had INDs accepted and moved forward in clinical development and has been a founder of eight biotech companies.

Prior to becoming Halia’s Chief Scientific Officer in January 2021 and CEO in March 2022, Dave was the CEO of Tolero Pharmaceuticals, which was acquired by Sumitomo Dainippon Pharma in 2017. He also served as Chief Scientific Officer at Montigen Pharmaceuticals prior to it’s acquisition by SuperGen Inc., and stayed on as Chief Scientific Officer at SuperGen to have oversight on early drug discovery and development. He was the founding Co-Director of the Center for Investigational Therapeutics at the Huntsman Cancer Institute; Associate Professor in the Department of Oncological Sciences at the University of Utah; and Associate Professor of Physiology & Developmental Biology at Brigham Young University. Dave received a PhD in cellular biology from University of Texas Health Science Center, San Antonio, TX.

Haven McCall, PhD

Founder and CEO, Canyon Labs
Haven McCall is the founder of Canyon Laboratories and has served as its CEO since its creation in October 2020. He is an experienced leader who has spent more than 23 years working in key positions at large multinational corporations in the areas of clinical research, quality, and regulatory. His doctoral studies at the University of Southern California focused on improving the standard of care for patients through risk mitigation and quality principles.

Haven is an active member of the Collaborative Institutional Training Initiative, Society of Clinical Research Associates, Regulatory Affairs Professionals Society, American Society for Quality, Project Management Institute and The Organization for Professionals in Regulatory Affairs. Over the last 20 years, he has participated within these organizations to drive improvements for industry best practices, regulations, guidance documents, standards, and directives.

Throughout his career, Dr. McCall has taught graduate-level courses in clinical research, quality, and regulatory at various universities. He currently teaches several graduate level regulatory science and biotechnology courses at Johns Hopkins University.

Phil Prentice, MBA

VP, Global Platform Leader, BD
Phil brings over 20 years of experience building innovative product platforms and leading high-growth businesses in the medical technology industry. His career spans a wide range of general management and executive leadership roles across medical device, orthodontics, and dental industries. He brings a deep understanding of what it takes to commercialize new, innovative solutions in a global, matrix environment.

Prior to BD, Phil was President, Orthodontics Group, at Henry Schein; the world’s largest dental and non-acute medical distributor. In addition, he has held business unit leadership and executive roles at both Danaher and Johnson & Johnson. While at Danaher, he led marketing for the dental portfolio of 3D CBCT imaging, digital scanning, and consumables products. During his time at Johnson & Johnson, Phil held roles focused on commercializing new innovative technology in advanced energy devices, hernia repair and restorative plastic surgery.

Phil began his career by serving in the U.S. Navy as a Nuclear Surface Warfare Officer where he led nuclear operations on the USS Dwight D Eisenhower (CVN-69) and was a Naval Reserve Officers Training Corp (NROTC) instructor at the University of Notre Dame. He holds a Bachelor of Science in Electrical Engineering from the University of Toledo, a Nuclear Engineering Officer certification from the U.S. Navy and a Master of Business Administration from Indiana University.

Josh Walker, MBA

Co-Founder and COO, Nomi Health
Josh Walker is a seasoned healthcare leader with over 20 years of experience. His expertise spans diverse regions, including the United States, Southeast Asia, India, the Middle East, and Europe. Throughout his career, Josh has successfully managed complex operational and strategic healthcare initiatives and led high-performing teams. He currently holds the position of Co-Founder and COO at Nomi Health. Previously, Josh served as the Chief Operating Officer of Upwell Health, driving substantial revenue growth in the first year. He has also held leadership roles at Red Pine Consulting, OptumInsight, J3 Bioscience, and Huntsman Biotechnology Corporation. Josh holds an MBA with a Special Emphasis in Healthcare from The George Washington University School of Business, along with other certifications and a Bachelor of Science in Behavioral Sciences and Health Economics from the University of Utah.